Best Life Sciences Companies in Geneva, Switzerland
The 77 best Life Sciences companies in Geneva, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: iOnctura.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Geneva
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | iOnctura Developer of pharmaceuticals to treat cancer | $112M | 24 mo ago | 20 | Lars van der Veen Founder & CTO | — | 39 patents Patents concentrated in health & consumer products | — |
| 2 | Spineart Developer of orthopedic implants and minimally invasive instruments | $108M | 8 mo ago | 289 | Stephane Mugnier-Jacob Co-Founder | WordPressApple iCloud MailMicrosoft 365+25 | 164 patents Spinal fixation and fusion devices, including intervertebral cages, disc prostheses, and pedicle screw systems. | — |
| 3 | ObsEva Developer of therapeutics for women's reproductive health and pregnancy | $95M | 69 mo ago | 27 | — | — | 210 patents Oxytocin antagonist therapeutics for fertility, preterm labor, and endometriosis treatment | — |
| 4 | Addex Therapeutics Developer of oral small molecules for neurological disorders | $71M | 33 mo ago | 24 | Tim Dyer CEO | Concrete CMSPHPApache HTTP Server+9 | — | — |
| 5 | Neurosterix Developer of allosteric modulator therapeutics for neurological disorders | $63M | 26 mo ago | — | Tim Dyer CEO | Cart FunctionalitySquarespace CommerceSquarespace+10 | — | — |
| 6 | PregLem Drugs for women's reproductive medicine | $58M | 222 mo ago | 157 | — | — | 159 patents Progesterone receptor modulators for uterine fibroids and related gynecological therapies. | — |
| 7 | Prexton Therapeutics Parkinson’s drugs that target the metabotropic glutamate receptors. | $43M | 112 mo ago | 5 | — | — | 68 patents Brain-penetrant chromone oxime allosteric modulators of metabotropic glutamate receptors for dyskinesia therapy | — |
| 8 | GeNeuro Developer of humanized monoclonal antibody for treating multiple sclerosis | $39M | 28 mo ago | 20 | — | — | 170 patents Therapeutic antibodies and compounds targeting HERV envelope proteins for disease treatment | — |
| 9 | Amal Therapeutics Developer of therapeutic vaccine for cancer | $37M | 91 mo ago | 27 | Laetitia Devy-Dimanche Chief Executive Officer | PHPLaravelAdobe Client Data Layer+12 | 101 patents Intracellular delivery of cell‑penetrating peptide complexes for cancer immunotherapy | — |
| 10 | Calypso Biotech Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases | $36M | 57 mo ago | 12 | — | — | 29 patents Therapeutic antibodies targeting IL‑15 cytokine and MMP‑9 protease for inflammatory disease treatment | — |
| 11 | STALICLA Manufacturer of precision medicinea for neurodevelopmental disorders | $22M | 11 mo ago | 26 | Lynn Durham Founder & CEO | TypeScriptVideoJSZone.js+8 | 116 patents Autism spectrum disorder diagnostics, biomarkers, and therapeutic pharmaceutical formulations. | — |
| 12 | EBAMed Platform offering non-invasive treatments | $17M | 28 mo ago | 7 | — | — | 26 patents Patents concentrated in health & consumer products | — |
| 13 | Chord Therapeutics Developer of drugs for the treatment of rare neurological diseases | $16M | 68 mo ago | 3 | — | — | 52 patents Targeted cladribine therapies for autoimmune neuromuscular and brain disorders | — |
| 14 | FIND Diagnostics Diagnostic tests for poverty-related diseases | $15M | 44 mo ago | 501 | William Rodriguez CEO | WordPressMySQLPHP+20 | — | 1 partnership |
| 15 | Andrew Alliance Provider of automated liquid handling tools and software for scientific labs | $14M | 88 mo ago | 5 | — | WordPressMySQLPHP+36 | 55 patents Automated liquid handling and lab robotics for microplate and pipette manipulation | — |
| 16 | QGel Hydrogel based cell culture system for drug discovery and drug-response assays | $12M | 114 mo ago | 15 | — | — | 43 patents Hydrogel-based 3D cell culture platforms for organoid growth and drug screening | — |
| 17 | EP Solutions Non-invasive electrophysiology tools for cardiac mapping | $10M | 21 mo ago | 6 | Marcin Gołębicki Chief Executive Officer | — | — | — |
| 18 | MaxiVAX Developing immunotherapies for treating cancer | $5M | 47 mo ago | 8 | Bernard Mach Co-Founder & Executive Chairman | — | 35 patents Implantable drug‑delivery capsules and immortalized myoblast cell platforms for therapeutic protein production | — |
| 19 | Viroblock Specialty company developing antiviral products for enveloped viruses | $5M | 171 mo ago | 9 | — | — | 26 patents Lipid-based antiviral formulations that inactivate enveloped viruses and inhibit gram‑positive bacteria. | — |
| 20 | Embion Technologies Developer of a synthetic biology platform for converting waste into useful chemicals for industrial uses | $5M | 54 mo ago | 13 | — | — | — | — |
| 21 | Release Tx Developer of encapsulated cell therapy device for the treatment of CNS diseases | $4M | 22 mo ago | — | Thomas Mehrling CEO | — | — | — |
| 22 | Terapet Developer of integrated imaging solutions for proton therapy and nuclear medicine | $4M | 27 mo ago | 8 | Raymond Miralbell Co-Founder & CSO | WordPressMySQLPHP+22 | 36 patents Patents concentrated in computing, sensing & instrumentation | — |
| 23 | Relief Therapeutics Developer of drugs for treating pulmonary and infectious diseases | $3M | 22 mo ago | 69 | — | JoomlaPHPUIKit+10 | — | — |
| 24 | MIKAJAKI Developer of eye health diagnostics products | $2M | 72 mo ago | 9 | Yann Voillot CEO | — | 9 patents Automated ocular ultrasound imaging systems for eye diagnostics | — |
| 25 | Adiposs Developer of medical imaging equipment for the diagnosis of cachexia | $2M | 11 mo ago | 7 | Justyna Plewka Co-Founder & COO | — | 13 patents Medical imaging contrast agents and therapeutic emulsions for diagnostic and nutritional applications. | — |
| 26 | Stemergie Biotechnology Developing therapeutics targeting the metabolism of cancer stem cells | $2M | 172 mo ago | — | Daniel Leutenegger Co-Founder | — | 11 patents Mitochondrial Complex III inhibitors for therapeutic disease treatment | — |
| 27 | MPC Developer of new generation of small molecules for cancer and degenerative diseases | $2M | 31 mo ago | — | Augustin Bettignies Co-Founder & Co-CEO | — | — | — |
| 28 | Kejako Researches and develops medical devices for the ophthalmic surgery sector | $807K | 99 mo ago | 3 | David ENFRUN Co-Founder & CEO | — | 20 patents Intraocular accommodative lenses and iris prosthetic implants for vision correction | — |
| 29 | Lascco Clinical-stage Biotech company developing technologies based on University/Academic research | $620K | 166 mo ago | — | — | — | 9 patents Peptide-based diagnostic assays for respiratory infections and IFN‑γ inhibitor therapies for motor neuron diseases | — |
| 30 | Epithelix Provider of 3D tissue and testing services for in-vitro drug testing for respiratory cells | $611K | 77 mo ago | — | Samuel Constant COO & Co-Founder | PHPGoogle MapsVimeo+11 | — | — |
| 31 | Neurosoft Bioelectronics Provider of soft implantable electrodes for neurological disorders | $208K | 1 mo ago | 7 | Nicolas Vachicouras Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | 1 award |
| 32 | Clee Medical Developer of neurosurgical tools and techniques | $170K | 3 mo ago | — | Matthew Lapinski Co-Founder & CEO | — | — | — |
| 33 | ABOLOGIX Developer of antibody therapeutics to treat non-Hodgkin´s lymphoma | $167K | 60 mo ago | — | Beat Imhof Co-Founder | — | — | — |
| 34 | SightIn Health AI-based ultrasound imaging tool for clinicians | $156K | 45 mo ago | 2 | — | — | — | — |
| 35 | Unilabs Provider of diagnostics services company | $138K | 124 mo ago | 14,200 | — | Google MapsAmazon Web ServicesMicrosoft Clarity+17 | — | — |
| 36 | ABCDx Provider of bio-markers for prognosis and diagnosis of brain injuries | $119K | 48 mo ago | 8 | Joan Montaner Co-Founder | WebflowGSAPLenis+11 | 4 patents Biomarker assays for traumatic brain injury and large vessel occlusion diagnostics | 1 partnership · 1 award |
| 37 | HekeTiss Provider of cell-therapy treatments for ulcerative skin conditions | $112K | 23 mo ago | — | Olivier Seauve Co-Founder | — | — | — |
| 38 | KYLYS Developer of technology to produce biomolecular reagents. | $112K | 37 mo ago | 4 | — | — | — | — |
| 39 | Endotelix Developer of solutions for treating antiphospholipid syndrome | $107K | 39 mo ago | — | Karim Brandt Co-Founder & CEO | — | — | — |
Top 12 Life Sciences companies in Geneva
#1
Series B · Plan les Ouates, Geneva · founded 2005 · 289 employees$108Mraised▾
Spineart is a developer of patented minimally invasive surgical instruments and orthopedic implants for spinal or other orthopedic surgeries. It offers a portfolio of implants includes cervical cages, fixation implants, posterior Ti cages, lateral Ti cages, interspinal fusion device and many more. The instruments are used for arthroplasty, cervical fixation, deformity, interbody fusion, and thoracolumbar fixation. Some of the products have received FDA clearance.
- Sep 2025Series B$31.3M
- Mar 2024Convertible Debt$22.5M
- Jun 2020Series B$52M
- Sep 2016Series A$33.5M
#2
Series B · Geneva, Geneva · founded 2017 · 26 employees$21.6Mraised▾
Manufacturer of precision medicinea for neurodevelopmental disorders. It uses DEPI technology platform to develop pipeline candidate STP7 a multifaceted mGluR5 NAM pipeline to for cocaine abuse and other neurological indications.
- Jun 2025Series B$2.5M
- Jan 2024Conventional Debt$3.8M
- Jan 2024Series B$13.6M
- Jul 2022Grant (prize money)$1.7M
#3
Series B · Geneva, Geneva · founded 2017 · 20 employees$111.7Mraised▾
Developer of pharmaceuticals to treat cancer. The company is developing a pipeline of next-generation, precision molecules for oncology indications which include IOA-244 and IOA-359 for solid tumors, and hematological malignancies and IOA-289 for pancreatic cancer.
- Jun 2024Series B$85.9M
- Dec 2022Grant (prize money)$18.6M
- Nov 2022Series A$1.2M
- Sep 2022Conventional Debt$403.9K
#4
Seed · Geneva, Geneva · founded 2019 · 7 employees$208.4Kraised▾
Provider of soft implantable electrodes for neurological disorders. The company offers its proprietary technology SOFT ECoG which is a subdural electrode made up of thin metal films of sub-micron thickness to achieve long-term bio-integration in the body, conforming to the static and dynamic mechanics of neural tissue. The company claims that the product is still under development and is not approved for human use.
- May 2026Seed$7.5M
- Mar 2023Grant (prize money)$38.4K
- Apr 2022Grant (prize money)—
- Apr 2022Seed$100K
#5
Series A · Geneva, Geneva · founded 2018 · 7 employees$2.2Mraised▾
Developer of medical imaging equipment for the diagnosis of cachexia. The ImageBAT is a CT contrast scanner for early detection of cachexia or early changes in body fat in cancer and COPD patients.
- Jul 2025Series A$5M
- Jan 2022Seed$2M
- Jun 2021Seed$111.3K
- Aug 2020Conventional Debt$109.3K
#6
Series A · Geneva, Geneva · founded 2024$63Mraised▾
Developer of allosteric modulator therapeutics for neurological disorders. The company uses proprietary high-throughput allosteric modulator drug discovery platform and a portfolio of preclinical neuroscience assets to develop muscarinic acetylcholine receptor positive allosteric modulator for the treatment of patients suffering from schizophrenia.
- Apr 2024Series A$63M
#7
Series A · Geneva, Geneva · founded 2013 · 6 employees$10.4Mraised▾
EP Solutions develops non-invasive electrophysiology tools for cardiac mapping. Its proprietary technology enables simultaneous mapping of all four cardiac chambers, and on both epi-and endocardial surfaces. Applications involve pre and post-operative diagnosis of complex cardiac rhythm disturbances.
- Sep 2024Series A$4M
- Dec 2016Series A$10.4M
#8
Public · Geneva, Geneva · founded 2002 · 24 employees$71Mraised▾
Developer of oral small molecules for neurological disorders. The company develops orally available allosteric modulators that bind to sites distinct from traditional orthosteric ones, potentially offering improved efficacy and safety over conventional drugs for conditions like Parkinson's disease and addiction. Their platform targets receptors such as mGlu5, mGlu2, and GABAB to address unmet needs in brain health.
- Sep 2023Grant (prize money)$4.3M
- Jul 2022Post IPO$4.2M
- Nov 2020Post IPO$2.8M
- Aug 2020Grant (prize money)—
#9
Public · Plan les Ouates, Geneva · founded 2006 · 20 employees$39.1Mraised▾
GeNeuro is a clinical stage company focussed on developing drugs for autoimmune diseases such as multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). It has developed GNbAC1, a humanized monoclonal antibody which neutralizes the MSRV-Env protein rather than targeting the patient's immune system. The candidate is currently in Phase IIb clinical development for MS. It is also planning to develop its platform for other neurological diseases and autoimmune diseases such as type 1 diabetes and chronic inflammatory demyelinating polyneuropathy.
- Feb 2024Post IPO$5.4M
- Dec 2021Grant (prize money)$7.3M
- Jul 2021Post IPO$7.1M
- Jan 2020Post IPO$19.3M
#10
Seed · Geneva, Geneva · founded 2024$170.4Kraised▾
Developer of neurosurgical tools and techniques. The company is developing advanced tools and imaging solutions that promise to revolutionize brain surgery and neurotherapy.
- Feb 2026Seed—
- Mar 2025Seed$170.4K
#11
Series A · Geneva, Geneva · founded 2018 · 7 employees$17Mraised▾
Platform offering non-invasive treatments. It is a medical device company developing innovative solutions for non-invasive and automated treatment of heart arrhythmias. The company utilizes advanced technologies such as proton therapy to improve treatment outcomes. EBAMed's products aim to provide efficient and painless solutions for patients suffering from cardiac arrhythmias. The company has secured significant funding to advance its technology and expand its product offerings.
- Jan 2024Series A$1.7M
- Jun 2023Series A$15.6M
- Sep 2022Seed$101K
- Sep 2020Grant (prize money)$2.8M
#12
Seed · Geneve, Geneva · founded 2023$3.9Mraised▾
Developer of encapsulated cell therapy device for the treatment of CNS diseases. The company is engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins to treat CNS hereditary diseases, focusing on Metachromatic Leukodystrophy.
- Aug 2024Seed$3.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Geneva researches in biotechnology
- University of Geneva20
- University Hospital of Geneva6
- Geneva College4
- EU Business School, Geneva1
- The Geneva Foundation1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.